This was an independent session organised by MGP without financial support or involvement from the pharmaceutical industry.
This site is intended for UK healthcare professionals
See also:
Dr Kevin Fernando Q&A on type 2 diabetes
Dr Kevin Fernando answers questions on the impact of type 2 diabetes on patients’ daily lives, differences between NICE and SIGN guidance, and key take-home messages for primary care
Latest video
Related articles
Prescribing summary cardOzempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited
- Independent professional body guideline
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
- Independent professional body guideline
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
More Videos
- Video
Dr Glenis Scadding Q&A on rhinitis
This session was supported by an educational grant from Mylan Ltd. Dr Glenis Scadding comments on the main presentations of rhinitis, its impact on patients’ daily lives, red flags for referral, and the main recommendations of the 2017 BSACI guideline
- Video
Guidelines Live 2018 overview with Dr Matthew Fay
Dr Matt Fay, Chair of Guidelines Live 2018, provides his thoughts on the programme from a primary care perspective, and summarises the meetings.
No comments yet